Early human trials of a new experimental HIV vaccine are promising.

In 97 percent of vaccine recipients, an essential part of the human immune
response was elicited by an HIV vaccine candidate, demonstrating promising
early findings.
A vaccine produced from an engineered version of a protein found in the HIV
virus was tested in a limited phase 1 experiment. This article aims to
prime the body to produce broadly neutralizing antibodies, which are
thought to be essential for developing an immune response against HIV.